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Interferon (IFN) was first described as a product of influenza virus-infected chick embryo cells, capable of inducing resistance to infection with homologous or heterologous viruses (Isaacs and Lindenmann, 1957) . Some years later, a functionally related protein (now called IFN-g or type II IFN) was described as an IFNlike virus-inhibitory protein produced by mitogen-activated human T lymphocytes (Wheelock, 1965) . Type I IFNs include numerous subtypes, of which IFN-a and IFN-b are the predominant forms (see review by van Boxel-Dezaire et al., 2006 in this issue of Immunity). Twelve separate functional IFN-a genes and proteins and a single IFN-b gene exist in humans.
Touted as a potentially useful antiviral drug, the study of IFN from the very beginning attracted wide attention. In the 1960s, Flash Gordon magazine featured a comic strip in which doctors in a space ship used IFN to cure a patient afflicted with a mysterious virus infection. Nevertheless, because efforts to purify and molecularly define IFN proteins remained fruitless for about 20 years, many scientists had been openly skeptical about properties ascribed to IFN, including its very existence. It was only after the successful cloning of IFN cDNAs and identification of IFN genes that IFN research joined the mainstream of the scientific enterprise (Gray and Goeddel, 1982; Nagata et al., 1980; Taniguchi et al., 1979) . This commentary serves as a brief introduction to a group of accompanying reviews summarizing the current state of knowledge in some of the most active areas of IFN research within the context of innate immunity and autoimmunity. My comments will focus on how views of the field of IFN research (especially of type I IFN) have been evolving over the nearly 50 year period since the first publications describing IFN (Table 1) . From Selective Antiviral Inhibitor to Multifunctional Cytokine Isaacs, Lindenmann, and other pioneers of IFN research had not anticipated that the significance of IFN would extend beyond the field of virology. In fact, an article in a leading textbook on IFN published more than 15 years after the original description of IFN proposed that the ''probable lack of other (than antiviral) cellular effects of interferons'' be part of a definition of IFNs (Lockart, 1973 ). Yet, as early as 1962, some investigators argued that murine IFN inhibited the growth of mouse cells in culture and that this activity could not be separated from the antiviral action of IFN (Paucker et al., 1962) . Almost concurrently, IFN was shown to inhibit the appearance of intracellular inclusions formed by Chlamydia psittaci, an obligate intracellular bacterium (Sueltenfuss and Pollard, 1962) . The latter finding was followed by demonstrations that type I IFN inhibits intracellular multiplication of protozoa, rickettsia, and other intracellular bacteria (reviewed in Stewart, 1979; Vilcek and Jahiel, 1970) . Among other early recognized pleiotropic activities of type I IFNs were also enhancement of the lytic action of cytotoxic T cells for tumor target cells (Lindahl et al., 1972) and enhancement of MHC antigen expression (Lindahl et al., 1976) . Other studies revealed that treatment with IFN can inhibit tumor growth in animals, an activity now known to be attributable to multiple mechanisms (Gresser et al., 1969) .
Naturally, today no one doubts that type I IFNs have multiple functions in addition to their well-known ability to inhibit virus replication. This is also true of IFN-g, which functions primarily as an immunomodulatory cytokine. It is useful, however, to remind ourselves that IFN was discovered by virologists who found what they had been looking for: an antiviral product of virusinfected cells responsible for viral interference. It took many years to change the ingrained concept of IFN as a specific and selective antiviral protein devoid of any other ''side effects. '' The real breakthrough in the understanding of the molecular mechanisms of IFN actions had to await the definition of IFN receptors and elucidation of signal transduction pathways triggered by the ligand-receptor interactions. During the first decade of IFN research, the prevailing view was that the IFN molecule itselfupon entering the cell and perhaps undergoing some metabolic changes-was the actual inhibitor of virus replication. Indirect evidence for IFN binding to the cell surface was first reported in the late 1960s (Friedman, 1967) . By the early 1980s, binding studies with radiolabeled IFN proteins had led to the conclusion that there are specific high-affinity cell-surface receptors for IFNs, that different subspecies of type I IFN (IFN-a and IFN-b) share a common receptor, and that receptors for type I and type II IFN are distinct (Aguet et al., 1982; Branca and Baglioni, 1981) . Molecular cloning and characterization of components of type I IFN receptors were largely completed by the mid-1990s (Domanski and Colamonici, 1996; Novick et al., 1994) . It is now clear that all type I IFNs bind to the same dimeric receptor, but different type I IFNs elicit somewhat different biological responses (van Boxel-Dezaire et al., 2006) .
Another important chapter in the annals of IFN research concerns the identification of signaling pathways responsible for IFN actions. Gradual elucidation of the details of the JAK-STAT signaling pathway activated by IFNs helped to clarify not only the molecular mechanisms responsible for IFN actions, but also laid the groundwork for understanding the actions of many other cytokines (Darnell et al., 1994) . The nuances and complexities of the multifaceted biology of type I IFN actions are reviewed in an accompanying review article (van Boxel-Dezaire et al., 2006) . Multiple Agents and Multiple Pathways Can Lead to IFN Induction Although the recognition that IFN is a pleiotropic cytokine was slow, it had taken less time to learn that many different stimuli, in addition to viruses, can trigger IFN production. Thus, IFN production was demonstrated in chickens, mice, and rabbits injected with a variety of bacteria or bacterial lipopolysaccharide (LPS) (Ho, 1964; Stinebring and Youngner, 1964) . IFN-g owes its discovery to the finding that the addition of phytohemagglutinin, a mitogenic lectin, to a suspension of human leucocytes elicited IFN production (Wheelock, 1965) . Crude filtrates from cultures of the fungus Penicillium stoloniferum were shown to induce IFN in mice and in tissue culture (Kleinschmidt et al., 1964) . (The filtrate was called ''statolon'' and shown earlier to have antiviral activity.) Of special significance was the demonstration that the active principle of ''statolon,'' and a similar fungal extract called ''helenine,'' was double-stranded RNA-likely originating from a polyhedral virus infecting the fungal cells. Double-stranded RNA from statolon or helenine, and also synthetic double-stranded RNA, poly (I).poly(C), readily triggered IFN production in intact animals or in cell cultures (Field et al., 1967) . Although hopes of using double-stranded RNA as a therapeutic agent for virus infections have not materialized, identification of double-stranded RNA as a potent IFN inducer provided researchers with a precious tool for the study of IFN induction pathways. In addition, it soon became apparent that double-stranded RNA plays a key role not only in IFN induction, but also in IFN action. Two of the IFN-induced proteins central to IFN's antiviral actions, 2 0 -5 0 oligoadenylate synthetase and doublestranded RNA-dependent protein kinase (PKR), were shown to require double-stranded RNA for their activation (Kerr et al., 1974; Lebleu et al., 1976) .
It was expected that identification of double-stranded RNA as a potent IFN inducer in the late 1960s would rapidly provide clues to the mechanism of IFN induction by viruses. After all, double-stranded RNA was known to be a byproduct of replication of many viruses, so wouldn't exposure of cells to double-stranded RNA simply mimic the process of IFN induction by viruses? In reality, the situation proved to be more complicated. Molecular pathways mediating cellular responses to doublestranded RNA remained largely unknown until the demonstration that toll-like receptor 3 (TLR3) recognizes double-stranded RNA (Alexopoulou et al., 2001) . As explained in more detail in the accompanying review (Stetson and Medzhitov, 2006), this cytosolic pathway is functional mainly in specialized cells, namely dendritic Sueltenfuss and Pollard, 1962 1964 IFN induced in animals by bacteria and endotoxin Ho, 1964; Stinebring and Youngner, 1964 1965 Description of IFN-g (type II IFN) Wheelock, 1965 Wheelock, 1967 Double-stranded RNA induces IFN Field et al., 1967 1969 IFN inhibits tumor growth in animals Gresser et al., 1969 Gresser et al., 1972 Gresser et al., -1976 Immunoregulatory actions of IFN are recognized Lindahl et al., 1976 Lindahl et al., , 1972 Lindahl et al., 1974 Lindahl et al., -1976 IFN-induced proteins mediating antiviral action are described Kerr et al., 1974; Lebleu et al., 1976 Lebleu et al., 1975 Identification of distinct subtypes of type I IFN proteins (IFN-a and -b) Havell et al., 1975 Description of elevated levels of IFN in patients with systemic lupus Skurkovich and Eremkina, 1975 -1977 Recognition of IFN's adverse effects in animals Gresser et al., 1975; Riviere et al., 1977 Riviere et al., 1979 Isolation and sequencing of human IFN-b cDNA Taniguchi et al., 1979 Taniguchi et al., 1980 Isolation, sequencing, and expression of human IFN-a cDNA Nagata et al., 1980 Purification and partial sequencing of human IFN-a and IFN-b proteins Knight et al., 1980; Zoon et al., 1980 Zoon et al., 1982 Isolation and sequencing of human IFN-g cDNA Gray and Goeddel, 1982 Elevated IFN concentrations described in HIV-infected patients, correlating with severity of disease DeStefano et al., 1982 DeStefano et al., 1985 ISRE recognition element identified in upstream region of IFN-inducible genes Friedman and Stark, 1985 Stark, 1988 Discovery of IRF transcription factor family Miyamoto et al., 1988 Miyamoto et al., 1990 Identification of ISGF-3 protein complex mediating activation of IFN-inducible genes Fu et al., 1990 Fu et al., 1990 Fu et al., -1996 Identification and characterization of type I IFN receptor components Novick et al., 1994; Domanski and Colamonici, 1996 1992 -1994 JAK-STAT signaling pathway identified as major pathway for IFN-induced gene expression Velazquez et al., 1992; Darnell et al., 1994 Darnell et al., 1995 Darnell et al., -1998 IRF-3 and IRF-7 found to play key roles in type I IFN induction Juang et al., 1998; Marie et al., 1998; Sato et al., 1998 Sato et al., 1999 Plasmacytoid (Kato et al., 2006; Yoneyama et al., 2004) . In addition to double-stranded RNA, other microbial components or products have been shown to trigger type I IFN production through other pathways, including single-stranded viral RNA (acting on TLR7 and TLR8) and viral or bacterial DNA (via TLR9). Although nucleic acids are arguably the most important activators of type I IFN production, bacterial LPS is now known to trigger IFN production in macrophages and DCs via TLR4 (Kawai and Akira, 2006; Stetson and Medzhitov, 2006) . Molecular pathways used by other stimuli known to trigger type I IFN production, e.g., some viral glycoproteins and other microbial components, have not yet been fully elucidated (Malmgaard, 2004) . Another shot in the arm for the study of molecular mechanisms of IFN induction was provided by the discovery of the new family of transcription factors, the IFN regulatory factors (IRFs), by Taniguchi and colleagues (Miyamoto et al., 1988) . The earliest-discovered members of this family, IRF-1 and IRF-2, were shown to be important in a variety of innate and adaptive immune responses, including T helper 1 responses and natural killer (NK) cell differentiation (Taniguchi et al., 2001) . Two other members of the IRF family, IRF-3 and IRF-7, have been found to play key roles in type I IFN gene activation (Juang et al., 1998; Marie et al., 1998; Sato et al., 1998) .
It has also become apparent that several IRF family members, including IRF-3, -5, and -7, are important in TLR signaling Kawai and Akira, 2006) . IRF family transcription factors play broader roles in TLR signaling that are not limited to IFN gene activation. For example, MyD88-dependent activation of IRF-5 is essential for the TLR-mediated induction of the proinflammatory cytokines TNF-a, IL-6, and IL-12, but not for IFN-a and IFN-b induction (Takaoka et al., 2005) . The molecular pathways of the complex processes of type I IFN induction are reviewed in the accompanying articles Stetson and Medzhitov, 2006) .
Good Interferon versus Bad Interferon
In the early days, IFN was believed to be a highly selective and specific antiviral agent devoid of any actions in uninfected cells and assumed to be completely nontoxic in the intact organism. The presumed lack of IFN toxicity served as an important argument in the effort to develop IFNs as therapeutic agents for the treatment of viral infections and cancer in the 1970s and early 1980s. And yet, results suggesting adverse actions of IFNs in the body were already at hand in the mid-1970s. Thus, injection of large doses of type I mouse IFN to newborn mice caused growth retardation and, eventually, death (Gresser et al., 1975) . The major histopathological finding was steatosis and necrosis of the liver. Mice given sublethal doses of IFN developed glomerulonephritis later in life. The biological relevance of these findings was recently corroborated by a study demonstrating that embryonic lethality seen in DNase II-deficient mice is due to the animals' inability to degrade DNA derived from erythroid precursors, which in turn triggers IFN-b production that induces expression of a specific set of IFN-responsive genes leading to embryonic lethality (Yoshida et al., 2005) .
Another surprising development was the gradual realization that endogenous IFN, produced in the body in the course of an infection, can be harmful-first clearly demonstrated in the model of lymphocytic choriomeningitis virus (LCMV) infection in newborn mice (Riviere et al., 1977) . Most of LCMV-infected animals died within 2-3 weeks, and surviving mice developed glomerulonephritis later in life. However, LCMV-infected newborn mice treated with a potent neutralizing antibody to type I mouse IFN survived and had a lower incidence of glomerulonephritis later in life.
Gradually, other evidence became available suggesting that IFN produced in the course of common virus infections, while serving as an inhibitor of virus replication, may also contribute to morbidity. Some of this evidence was gleaned from early clinical studies with natural or recombinant IFNs revealing that administration of IFN-a or IFN-b to patients produced fever, fatigue, malaise, myalgia, and anemia (Vilcek, 1984) . It became apparent that similar ''flu-like'' symptoms seen in many common acute virus infections are due, at least in part, to the production of endogenous IFN. Thus, administration of IFNa by intranasal spray protected volunteers from rhinovirus infection. However, intranasal IFN administration also produced a local inflammatory reaction, not unlike that seen in patients suffering from naturally acquired rhinovirus infection (Merigan et al., 1973; Vilcek, 1984) .
Another indication of possible adverse effects of IFN came from studies showing that sera of many patients with autoimmune diseases, especially patients with systemic lupus erythematosus (SLE), have elevated amounts of type I IFN (Hooks et al., 1982; Preble et al., 1982; Skurkovich and Eremkina, 1975) . Although the exact significance of these observations was not understood at the time, the fact that the presence of IFN seemed to correlate with disease activity suggested a pathogenetic, rather than protective, activity. Further support for the role of type I IFN in autoimmunity was gained when it had became apparent that IFN therapy may sometimes cause or aggravate autoimmune disorders, including thyroiditis, diabetes, arthritis, and vasculitis (Banchereau and Pascual, 2006) .
Much more information about the source and role of IFN in SLE and some other autoimmune disorders is available today, as reviewed in the accompanying article (Banchereau and Pascual, 2006) . A central hypothesis proposed by these authors is that overproduction of type I IFN in SLE causes activation of immature myeloid DCs, which in turn leads to the activation and expansion of autoreactive T cells and B cells. Further amplification of autoimmune responses then occurs through additional interactions involving, among others, TLR7-or TLR9-mediated activation of plasmacytoid DCs by nucleic acid containing immune complexes.
An interesting concept concerns the crossregulation of IFN and tumor necrosis factor (TNF) in autoimmunity (Banchereau and Pascual, 2006; Palucka et al., 2005) . It has been known for a while that some patients treated with anti-TNF agents may develop anti-nuclear antibodies, antibodies to double-stranded DNA, and in rare occasions, SLE (Feldmann and Maini, 2001 ). The latter findings in patients treated with anti-TNF agents correlate with enhanced IFN production by plasmacytoid DCs, suggesting that TNF inhibits type I IFN generation. Conversely, IFN-b was found to inhibit TNF production by microglia, which might partially explain the beneficial effect of IFN-b in multiple sclerosis (Teige et al., 2003) .
Elevated amounts of type I IFN with properties similar to the IFN found in the sera of SLE patients were also demonstrated in a high percentage of AIDS patients (DeStefano et al., 1982) . The presence and the amounts of IFN in the AIDS patients' sera generally correlated with the severity of disease, suggesting that IFN may contribute to immune dysfunction. However, the possible mechanisms whereby IFN may contribute to AIDS pathogenesis remained mysterious for a long time. We now appreciate the fact that type I IFNs can sensitize cells to apoptotic signals, especially to virus-induced apoptosis (see review by Stetson and Medzhitov, 2006 in this issue of Immunity). As far as I know, there exists no direct evidence that IFN sensitizes CD4 + T cells to HIV-induced cell death, but such action is a plausible possibility. It is also possible that depletion of CD4 + T cells may be an indirect consequence of IFN action. A recently proposed hypothesis links the depletion of CD4 + T cells in HIV-infected patients to IFN's ability to enhance the generation of TNF-related apoptosis-inducing ligand (TRAIL) and its receptor DR5 (Herbeuval et al., 2005) .
Studies in animals indicate that in certain situations IFN may promote, rather than inhibit, the multiplication of an infectious agent. Type I IFN receptor-deficient mice were shown to be markedly more resistant to infection with a high dose Listeria monocytogenes (Auerbuch et al., 2004) . At 3 days after inoculation, wild-type mice contained a thousand times more bacteria in their spleens than IFN receptor-deficient mice. Resistance to Listeria infection correlated with elevated amounts of interleukin 12 in the blood and increased numbers of spleen macrophages producing TNF. A similar enhanced resistance to Listeria was seen in IRF-3-deficient mice (O'Connell et al., 2004) . The results of these studies suggest that Listeria monocytogenes is exploiting an IFN-driven innate immune mechanism to promote its pathogenesis. Conclusion Our understanding of the nature and roles of type I IFNs is very different today from what it was during the ''romantic period'' when nearly supernatural properties had been attributed to IFN. We now appreciate the fact that IFNs play important roles in host defenses, but we understand that they can also be harmful when produced at the wrong time or wrong place. On the positive side, although the clinical utility of IFNs has not met the rosy expectations of some of its most enthusiastic promoters, several recombinant type I IFN products have earned a solid foothold in the pharmaceutical armamentarium. One viral infection in which IFN-a is widely used (frequently in combination with the nucleoside analog Ribavirin) is chronic hepatitis C. Other currently approved clinical applications of IFN-a are for the treatment of some neoplasias, including certain forms of chronic myelogenous leukemia and malignant melanoma. Recombinant IFN-b is being used for the treatment of relapsing forms of multiple sclerosis. As is frequently the case with other therapeutics, a thorough understanding of the mechanism of IFN's beneficial actions in malignancies and in multiple sclerosis has lagged behind its therapeutic utility.
We have made enormous strides in the understanding of the molecular mechanisms of regulation of IFN induction and synthesis and in the elucidation of the mechanisms of IFN action. The most recent advances in these areas are highlighted in the four accompanying reviews published in this issue (Banchereau and Pascual, 2006; Stetson and Medzhitov, 2006; van Boxel-Dezaire et al., 2006) . Darnell, J.E., Jr., Kerr, I.M., and Stark, G.R. (1994) . Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421.
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